1. Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2
- Author
-
Kerry L. Hilligan, Sivaranjani Namasivayam, Chad S. Clancy, Paul J. Baker, Samuel I. Old, Victoria Peluf, Eduardo P. Amaral, Sandra D. Oland, Danielle O’Mard, Julie Laux, Melanie Cohen, Nicole L. Garza, Bernard A. P. Lafont, Reed F. Johnson, Carl G. Feng, Dragana Jankovic, Olivier Lamiable, Katrin D. Mayer-Barber, and Alan Sher
- Subjects
Science - Abstract
Abstract Type-1 and type-3 interferons (IFNs) are important for control of viral replication; however, less is known about the role of Type-2 IFN (IFNγ) in anti-viral immunity. We previously observed that lung infection with Mycobacterium bovis BCG achieved though intravenous (iv) administration provides strong protection against SARS-CoV-2 in mice yet drives low levels of type-1 IFNs but robust IFNγ. Here we examine the role of ongoing IFNγ responses to pre-established bacterial infection on SARS-CoV-2 disease outcomes in two murine models. We report that IFNγ is required for iv BCG induced reduction in pulmonary viral loads, an outcome dependent on IFNγ receptor expression by non-hematopoietic cells. Importantly, we show that BCG infection prompts pulmonary epithelial cells to upregulate IFN-stimulated genes with reported anti-viral activity in an IFNγ-dependent manner, suggesting a possible mechanism for the observed protection. Finally, we confirm the anti-viral properties of IFNγ by demonstrating that the recombinant cytokine itself provides strong protection against SARS-CoV-2 challenge when administered intranasally. Together, our data show that a pre-established IFNγ response within the lung is protective against SARS-CoV-2 infection, suggesting that concurrent or recent infections that drive IFNγ may limit the pathogenesis of SARS-CoV-2 and supporting possible prophylactic uses of IFNγ in COVID-19 management.
- Published
- 2023
- Full Text
- View/download PDF